Please sign in to follow a disease.
Uterine carcinosarcoma
Clinical trials for Uterine carcinosarcoma explained in plain language.
Never miss a new study
Get alerted when new Uterine carcinosarcoma trials appear
Sign up with your email to follow new studies for Uterine carcinosarcoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Matched conditions: UTERINE CARCINOSARCOMA
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for aggressive uterine cancer: targeted drug trial shows promise
Disease control OngoingThis study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of ut…
Matched conditions: UTERINE CARCINOSARCOMA
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo shows promise for rare, aggressive uterine cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. About 40 participants will receive the treatment, and researchers will also…
Matched conditions: UTERINE CARCINOSARCOMA
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …
Matched conditions: UTERINE CARCINOSARCOMA
Phase 1 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC